Advancing a functional genomics for schizophrenia: Psychopathological and cognitive phenotypes in mutants with gene disruption

Brain Research Bulletin

Volumn 83, Issue 3-4, 2010, Pages 162-176

  Kirby, Brian P ^a   Waddington, John L ^a   O'Tuathaigh, Colm M P ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Cognitive dysfunction; Endophenotypes; Genomics; Mutant behaviour; Positive and negative symptoms; Schizophrenia

Indexed keywords

CALCINEURIN; CATECHOL METHYLTRANSFERASE; DEXTRO AMINO ACID OXIDASE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE TRANSPORTER; DYSBINDIN; GLYCINE; GLYCOGEN SYNTHASE KINASE 3BETA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B;

COGNITIVE DEFECT; DOPAMINERGIC ACTIVITY; FUNCTIONAL GENOMICS; GENE DISRUPTION; GENE INTERACTION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MENTAL DISEASE; MUTANT; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GENOMICS; HUMANS; MUTATION; PHENOTYPE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77955717936     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.09.010     Document Type: Review

References (209)

1. 2+-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:9876-9881.
2. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., Tanzi R.E., Bertram L.M.J. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 2008, 40:827-834.
3. Almond S.L., Fradley R.L., Armstrong E.J., Heavens R.B., Rutter A.R., Newman R.J., Chiu C.S., Konno R., Hutson P.H., Brandon N.J. Behavioral and biochemical characterization of a mutant mouse train lacking d-amino acid oxidase activity and its implications for schizophrenia. Mol. Cell. Neurosci. 2006, 32:324-334.
4. Arguello P.A., Gogos J.A. Modeling madness in mice: one piece at a time. Neuron 2006, 52:179-196.
5. Austin C.P., Ky B., Ma L., Morris J.A., Shughrue P.J. Expression of disrupted-in-schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development. Neuroscience 2004, 124:3-10.
6. Babovic D., O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Tighe O., Croke D.T., Karayiorgou M., Gogos J.A., Cotter D., Waddington J.L. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 2008, 155:1021-1029.
7. Babovic D, O'Tuathaigh C.M., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., Karayiorgou M., Gogos J.A., Cotter D., Waddington J.L. Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice. Behav. Brain Res. 2007, 183:236-239.
8. Ballard T.M., Pauly-Evers M., Higgins G.A., Ouagazzal A.M., Mutel V., Borroni E., Kemp J.A., Bluethmann H., Kew J.N. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J. Neurosci. 2002, 22:6713-6723.
9. Barnett J.H., Scoriels L., Munafò M.R. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol. Psychiatry 2008, 64:137-144.
10. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
11. Basu A.C, Tsai G.E., Ma C.L., Ehmsen J.T., Mustafa A.K., Han L., Jiang Z.I., Benneyworth M.A., Froimowitz M.P., Lange N., Snyder S.H., Bergeron R., Coyle J.T. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behaviour. Mol. Psychiatry 2009, 14:719-727.
12. Beaulieu J.M., Tirotta E., Sotnikova T.D., Masri B., Salahpour A., Gainetdinov R.R., Borrelli E., Caron M.G. Regulation of Akt signalling by D2 and D3 dopamine receptors in vivo. J. Neurochem. 2007, 27:881-885.
13. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., Agam G. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr. Res. 2009, 90:41-51.
14. Bersudsky Y., Shaldubina A., Kozlovsky N., Woodgett J.R., Agam G., Belmaker R.H. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav. Pharmacol. 2008, 19:217-224.
15. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., Graham D., Tsankova N.M., Bolanos C.A., Rios M., Monteggia L.M., Self D.W., Nestler E.J. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311:864-868.
16. Bertram L. Genetic research in schizophrenia: new tools and future perspectives. Schizophr. Bull. 2008, 34:806-812.
17. Bhardwaj S.K., Baharnoori M., Sharif-Askari B., Kamath A., Williams S., Srivastava L.K. Behavioral characterization of dysbindin-deficient sandy mice. Behav. Brain Res. 2009, 197:435-441.
18. Bickel S., Lipp H.P., Umbricht D. Impaired attentional modulation of auditory evoked potentials in N-methyl-d-aspartate NR1 hypomorphic mice. Genes Brain Behav. 2007, 5:558-568.
19. Bickel S., Lipp H.P., Umbricht D. Early auditory sensory processing deficits in mouse mutants with reduced NMDA receptor function. Neuropsychopharmacology 2008, 33:1680-1689.
20. Blackwood D.H., Fordyce A., Walker M.T., St.Clair D.M., Porteous D.J., Muir W.J. Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am. J. Hum. Genet. 2001, 69:428-433.
21. Boks M.P., Rietkerk T., van de Beek M.H., Sommer I.E., de Koning T.J., Kahn R.S. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. Eur. Neuropsychopharmacol. 2007, 17:567-572.
22. Bora E., Yucel M., Fornito A., Berk M., Pantelis C. Major psychoses with mixed psychotic and mood symptoms: are mixed psychoses associated with different neurobiological markers?. Acta Psychiatr. Scand. 2008, 118:172-187.
23. Boucher A.A., Arnold J.C., Duffy L., Schofield P.R., Micheau J., Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology 2007, 192:325-336.
24. Boucher A.A., Hunt G.E., Karl T., Micheau J., McGregor I.S., Arnold J.C. Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 2007, 149:861-870.
25. Boulay D., Pichat P., Dargazanli G., Estenne-Bouhtou G., Terranova J.P., Rogacki N., Stemmelin J., Coste A., Lanneau C., Desvignes C., Cohen C., Alonso R., Vigé X., Biton B., Steinberg R., Sevrin M., Oury-Donat F., George P., Bergis O., Griebel G., Avenet P., Scatton B. Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol. Biochem. Behav. 2008, 91:47-58.
26. Braff D.L., Freedman R., Schork N.J., Gottesman I.I. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 2007, 33:21-32.
27. Bramon E., Dempster E., Frangou S., Shaikh M., Walshe M., Filbey F.M., McDonald C., Sham P., Collier D.A., Murray R. Neuregulin-1 and the P300 waveform-a preliminary association study using a psychosis endophenotype. Schizophr. Res. 2008, 103:178-185.
28. Brodkin E.S., Hagemann A., Nemetski S.M., Silver L.M. Social approach-avoidance behavior of inbred mouse strains towards DBA/2 mice. Brain Res. 2004, 1002:151-157.
29. Brody S.A., Dulawa S.C., Conquet F., Geyer M.A. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol. Psychiatry 2004, 9:35-41.
30. Bubenikova-Valesova V., Horacek J., Vrajova M., Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci. Biobehav. Rev. 2008, 32:1014-1023.
31. Burdick K.E., Goldberg T.E., Funke B., Bates J.A., Lencz T., Kucherlapati R., Malhotra A.K. DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr. Res. 2007, 89:169-172.
32. Burmistrova O.A., Goltsov A.Y., Abramova L.I., Kaleda V.G., Orlova V.A., Rogaev E.I. MicroRNA in schizophrenia: genetic and expression analysis of miR-130b (22q11). Biochemistry 2007, 72:578-582.
33. Callicott J.H., Straub R.E., Pezawas L., Egan M.F., Mattay V.S., Hariri A.R., Verchinski B.A., Meyer-Lindenberg A., Balkissoon R., Kolachana B., Goldberg T.E., Weinberger D.R. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8627-8632.
34. Cannon T.D., Hennah W., van Erp T.G., Thompson P.M., Lonnqvist J., Huttunen M., Gasperoni T., Tuulio-Henriksson A., Pirkola T., Toga A.W., Kaprio J., Mazziotta J., Peltonen L. Association of DISC1/TRAX haplotypes with schizophrenia, reduced gray matter, and impaired short- and long-term memory. Arch. Gen. Psychiatry 2005, 62:1205-1213.
35. Carpenter W.T., Buchanan R.W., Kirkpatrick B., Tamminga C., Wood F. Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch. Gen. Psychiatry 1993, 50:825-831.
36. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
37. Chen J., Lipska B.K., Weinberger D.R. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol. Psychiatry 2006, 59:1180-1188.
38. Chen Y.J., Johnson M.A., Lieberman M.D., Goodchild R.E., Schobel S., Lewandowski N., Rosoklija G., Liu R.C., Gingrich J.A., Small S., Moore H., Dwork A.J., Talmage D.A., Role L.W. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J. Neurosci. 2008, 28:6872-6883.
39. Chubb J.E., Bradshaw N.J., Soares D.C., Porteous D.J., Millar J.K. The DISC locus in psychiatric illness. Mol. Psychiatry 2008, 13:36-64.
40. Clapcote S.J., Lipina T.V., Millar J.K., Mackie S., Christie S., Ogawa F., Lerch J.P., Trimble K., Uchiyama M., Sakuraba Y., Kaneda H., Shiroishi T., Houslay M.D., Henkelman R.M., Sled J.G., Gondo Y., Porteous D.J., Roder J.C. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 2007, 54:387-402.
41. Corvin A., McGhee K.A., Murphy K., Donohoe G., Nangle J.M., Schwaiger S., Kenny N., Clarke S., Meagher D., Quinn J., Scully P., Baldwin P., Browne D., Walsh C., Waddington J.L., Morris D.W., Gill M. Evidence for association and epistasis at the DAOA/G30 and d-amino acid oxidase loci in an Irish schizophrenia sample. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144:949-953.
42. Cox M.M., Tucker A.M., Tang J., Talbot K., Richer D.C., Yeh L., Arnold S.E. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav. 2009, 8:390-397.
43. Coyle J.T Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 2006, 26:365-384.
44. De La Garza R. Endotoxin- or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: focus on anhedonia. Neurosci. Biobehav. Rev. 2005, 29:761-770.
45. DeRosse P., Hodgkinson C.A., Lencz T., Burdick K.E., Kane J.M., Goldman D., Malhotra A.K. Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Biol. Psychiatry 2007, 61:1208-1210.
46. Desbonnet L., Waddington J.L., O'Tuathaigh C.M. Mutant models for genes associated with schizophrenia. Biochem. Soc. Trans. 2009, 37:308-312.
47. Desbonnet L., Waddington J.L., O'Tuathaigh C.M. Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes?. Behav Brain Res. 2009, 204:258-273.
48. Di Giorgio A., Blasi G., Sambataro F., Rampino A., Papazacharias A., Gambi F., Romano R., Caforio G., Rizzo M., Latorre V., Popolizio T., Kolachana B., Callicott J.H., Nardini M., Weinberger D.R., Bertolino A. Association of the SerCys DISC1 polymorphism with human hippocampal formation gray matter and function during memory encoding. Eur. J. Neurosci. 2008, 28:2129-2136.
49. Donohoe G., Morris D.W., Clarke S., McGhee K.A., Schwaiger S., Nangle J.M., Garavan H., Robertson I.H., Gill M., Corvin A. Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. Neuropsychologia 2007, 45:454-458.
50. Donohoe G., Morris D.W., De Sanctis P., Magno E., Montesi J.L., Garavan H.P., Robertson I.H., Javitt D.C., Gill M., Corvin A.P., Foxe J.J. Early visual processing deficits in dysbindin-associated schizophrenia. Biol. Psychiatry 2008, 63:484-489.
51. Dragin N., Shi Z., Madan R., Karp C.L., Sartor M.A., Chen C., Gonzalez F.J., Nebert D.W. Phenotype of the Cyp1a1/1a2/1b1-/- triple-knockout mouse. Mol. Pharmacol. 2008, 73:1844-1856.
52. Drew M.R., Simpson E.H., Kellendonk C., Herzberg W.G., Lipatova O., Fairhurst S., Kandel E.R., Malapani C., Balsam P.D. Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing. J. Neurosci. 2007, 27:7731-7739.
53. Duan X., Chang J.H., Ge S., Faulkner R.L., Kim J.Y., Kitabatake Y., Liu X.B., Yang C.H., Jordan J.D., Ma D.K., Liu C.Y., Ganesan S., Cheng H.J., Ming G.L., Lu B., Song H. Disrupted-in-schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007, 130:1146-1158.
54. Duffy L., Cappas E., Scimone A., Schofield P.R., Karl T. Behavioral profile of a heterozygous mutant mouse model for EGF-like domain neuregulin 1. Behav. Neurosci. 2008, 122:748-759.
55. Duffy S., Labrie V., Roder J.C. d-Serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning. Neuropsychopharmacology 2008, 33:1004-1018.
56. Duncan G.E., Moy S.S., Lieberman J.A., Koller B.H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 2006, 184:190-200.
57. Duncan G.E., Moy S.S., Perez A., Eddy D.M., Zinzow W.M., Lieberman J.A. Deficits in senosrimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav. Brain Res. 2004, 153:507-519.
58. Eells J.B, Misler J.A., Nikodem V.M. Reduced tyrosine hydroxylase and GTP cyclohydrolase mRNA expression, tyrosine hydroxylase activity, and associated neurochemical alterations in Nurr1-null heterozygous mice. Brain Res. Bull. 2006, 70:186-195.
59. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6917-6922.
60. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004, 36:131-137.
61. Fanous A.H., Kendler K.S. Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature. Curr. Psychiatry Rep. 2008, 10:164-170.
62. Farh K.K., Grimson A., Jan C., Lewis B.P., Johnston W.K., Lim L.P., Burge C.B., Bartel D.P. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005, 310:1817-1821.
63. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2-sulonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 2008, 326:209-217.
64. Feng Y.Q., Zhou Z.Y., He X., Wang H., Guo X.L., Hao C.J., Guo Y., Zhen X.C., Li W. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr. Res. 2008, 106:218-228.
65. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 2008, 9:102-114.
66. Fradley R.L., O'Meara G.F., Newman R.J., Andrieux A., Job D., Reynolds D.S. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. 2005, 163:257-264.
67. Frankland P.W., Sakaguchi M., Arruda-Carvalho M. Starting at the endophenotype: a role for alpha-CaMKII in schizophrenia?. Mol Brain 2009, 1:5.
68. Gainetdinov R.R. Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 377:301-313.
69. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001, 24:527-533.
70. Gerlai R., Pisacane P., Erickson S. Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Behav. Brain Res. 2000, 109:219-227.
71. Goghari V.M., Sponheim S.R. Differential association of the COMT Val158Met polymorphism with clinical phenotypes in schizophrenia and bipolar disorder. Schizophr. Res. 2008, 103:186-191.
72. Gogos J.A. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder. Int. Rev. Neurobiol. 2007, 78:397-422.
73. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behaviour. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9991-9996.
74. Goldman-Rakic P.S. The cortical dopamine system: role in memory and cognition. Adv. Pharmacol. 1998, 42:707-711.
75. Golub M.S., Germann S.L., Lloyd K.C. Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Brain Res. 2004, 153:159-170.
76. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
77. Gray L., van den Buuse M., Scarr E., Dean B., Hannan A.J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor upregulation. Int. J. Neuropsychopharmacol. 2009, 12:45-60.
78. Guillin O., Abi-Dargham A., Laruelle M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 2007, 78:1-39.
79. Guo X., Hamilton P.J., Reish N.J., Sweatt J.D., Miller C.A., Rumbaugh G. Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioural abnormalities that model symptoms of schizophrenia. Neuropsychopharmacology 2009, 34:1659-1672.
80. Hains A.B., Arnsten A.F. Molecular mechanisms of stress-induced prefrontal cortical impairment: implications for mental illness. Learn. Mem. 2008, 15:551-564.
81. Hall J., Whalley H.C., Job D.E., Baig B.J., McIntosh A.M., Evans K.L., Thomson P.A., Porteous D.J., Cunningham-Owens D.G., Johnstone E.C., Lawrie S.M. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat. Neurosci. 2006, 9:1477-1488.
82. Han D.H., Kee B.S., Min K.J., Lee Y.S., Na C., Park D.B., Lyoo I.K. Effects of catechol-O-methyltransferase Val158Met polymorphism on the cognitive stability and aggression in the first-onset schizophrenic patients. Neuroreport 2006, 17:95-99.
83. Han D.H., Park D.B., Na C., Kee B.S., Lee Y.S. Association of aggressive behavior in Korean male schizophrenic patients with polymorphisms in the serotonin transporter promoter and catecholamine-O-methyltransferase genes. Psychiatry Res. 2004, 129:29-37.
84. Hansen T., Olsen L., Lindow M., Jakobsen K.D., Ullum H., Jonsson E., Andreassen O.A., Djurovic S., Melle I., Agartz I., Hall H., Timm S., Wang A.G., Werge T. Brain expressed microRNAs implicated in schizophrenia etiology. PLoS ONE 2007, 2:e873.
85. Harrison P.J., Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry 2006, 60:132-140.
86. Harrison P.J., Lyon L., Sartorius L.J., Burnet P.W., Lane T.A. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function, and involvement in schizophrenia. J. Psychopharmacol. 2008, 22:308-322.
87. Hashimoto A., Konno R., Yano H., Yoshikawa M., Tamaki R., Matsumoto H., Kobayashi H. Mice lacking d-amino acid oxidase activity exhibit marked reduction of methamphetamine-induced stereotypy. Eur. J. Pharmacol. 2008, 586:221-225.
88. Hashimoto A., Yoshikawa M., Niwa A., Konno R. Mice lacking d-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801. Brain Res. 2005, 1033:210-215.
89. Hattori S., Murotani T., Matsuzaki S., Ishizuka T., Kumamoto N., Takeda M., Tohyama M., Yamatodani A., Kunugi H., Hashimoto R. Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem. Biophys. Res. Commun. 2008, 373:298-302.
90. Hikida T., Jaaro-Peled H., Seshadri S., Oishi K., Hookway C., Kong S., Wu D., Xue R., Andradé M., Tankou S., Mori S., Gallagher M., Ishizuka K., Pletnikov M., Kida S., Sawa A. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14501-14506.
91. Hodgkinson C.A., Goldman D., Ducci F., DeRosse P., Caycedo D.A., Newman E.R., Kane J.M., Roy A., Malhotra A.K. The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations. Neuropsychopharmacology 2007, 32:190-196.
92. Hong J.P., Lee J.S., Chung S., Jung J., Yoo H.K., Chang S.M., Kim C.Y. New functional single nucleotide polymorphism (Ala72Ser) in the COMT gene is associated with aggressive behavior in male schizophrenia. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2008, 147:658-660.
93. Hu X., Hicks C.W., He W., Wong P., Macklin W.B., Trapp B.D., Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 2006, 9:1520-1525.
94. Huotari M., García-Horsman J.A., Karayiorgou M., Gogos J.A., Männistö P.T. d-Amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology 2004, 172:1-10.
95. Ikeda M., Hikita T., Taya S., Uraguchi-Asaki J., Toyo-oka K., Wynshaw-Boris A., Ujike H., Inada T., Takao K., Miyakawa T., Ozaki N., Kaibuchi K., Iwata N. Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia. Hum. Mol. Genet. 2008, 17:3212-3222.
96. Purcell S.M., Wray N.R., Stone J.L., Visscher M.C., O'Donovan P.M., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752. International Schizophrenia Consortium.
97. Ivleva E., Thaker G., Tamminga C.A. Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder. Schizophr. Bull. 2008, 34:734-742.
98. Jablensky A. The conflict of the nosologists: views on schizophrenia and manic-depressive illness in the early part of the 20th century. Schizophr. Res. 1999, 39:95-100.
99. John B., Enright A.J., Aravin A., Tuschl T., Sander C., Marks D.S. Human microRNA targets. PLoS Biol. 2004, 2:e363.
100. Kamiya A., Kubo K., Tomoda T., Takaki M., Youn R., Ozeki Y., Sawamura N., Park U., Kudo C., Okawa M., Ross C.A., Hatten M.E., Nakajima K., Sawa A. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat. Cell Biol. 2005, 7:1167-1178.
101. Kapur S., Mizrahi R., Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 2005, 79:59-68.
102. Karl T., Duffy L., Scimone A., Harvey R.P., Schofield P.R. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav. 2007, 6:677-687.
103. Karlsson R.M, Tanaka K., Heilig M., Holmes A. Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist. Biol. Psychiatry 2008, 64:810-814.
104. Karlsson R.M., Tanaka K., Saksida L.M., Bussey T.J., Heilig M., Holmes A. Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology 2009, 34:1578-1589.
105. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum cause persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603-615.
106. Kim Y.R., Kim J.H., Kim S.J., Lee D., Min S.K. Catechol-O-methyltransferase Val158Met polymorphism in relation to aggressive schizophrenia in a Korean population. Eur. Neuropsychopharmacol. 2008, 18:820-825.
107. Kocerha J., Faghihi M., Lopez-Toledano M.A., Huang J., Ramsey A.J., Caron M.G., Sales N., Willoughby D., Elmen J., Hansen H.F., Orum H., Kauppinen S., Kenny P.J., Wahlestedt C. Micro-RNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3507-3512.
108. Koga M., Ishiguro H., Horiuchi Y., Albalushi T., Inada T., Iwata N., Ozaki N., Ujike H., Muratake T., Someya T., Arinami T. Failure to confirm the association between the FEZ1 gene and schizophrenia in a Japanese population. Neurosci. Lett. 2007, 417:326-329.
109. Koh H.Y., Kim D., Lee J., Lee S., Shin H.S. Deficits in social behavior and sensorimotor gating in mice lacking phospholipase Cbeta1. Genes Brain Behav. 2008, 7:120-128.
110. Koike H., Arguello P.A., Kvajo M., Karayiorgou M., Gogos J.A. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:3693-3697.
111. Krishnan V., Han M.H., Mazei-Robison M., Iñiguez S.D., Ables J.L., Vialou V., Berton O., Ghose S., Covington H.E., Wiley M.D., Henderson R.P., Neve R.L., Eisch A.J., Tamminga C.A., Russo S.J., Bolaños C.A., Nestler E.J. AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol. Psychiatry 2008, 64:691-700.
112. Krivoy A., Fischel T., Weizman A. The possible involvement of metabotropic glutamate receptors in schizophrenia. Eur. Neuropsychopharmacol. 2008, 18:395-405.
113. Kvajo M., McKellar H., Arguello P.A., Drew L.J., Moore H., MacDermott A.B., Karayiorgou M., Gogos J.A. A mutation in mouse Disc 1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7076-7081.
114. Kwon C.H., Luikart B.W., Powell C.M., Zhou J., Matheny S.A., Zhang W., Li Y., Baker S.J., Parada L.F. Pten regulates neuronal arborization and social interaction in mice. Neuron 2006, 50:377-388.
115. Labrie V., Lipina T., Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 2008, 200:217-230.
116. Lai W.S., Xu B., Westphal K.G., Paterlini M., Olivier B., Pavlidis P., Karayiorgou M., Gogos J.A. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16906-16911.
117. Li D., He L. G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies. Genetics 2007, 175:917-922.
118. Li M., Budin R., Fleming A.S., Kapur S. Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. Psychopharmacology 2005, 181:600-610.
119. Li W, Zhou Y., Jentsch J.D., Brown R.A., Tian X., Ehninger D., Hennah W., Peltonen L., Lönnqvist J., Huttunen M.O., Kaprio J., Trachtenberg J.T., Silva A.J., Cannon T.D. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:18280-18285.
120. Lichtenstein P., Yip B.H., Björk C., Pawitan Y., Cannon T.D., Sullivan P.F., Hultman C.M. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009, 373:234-239.
121. Lin H.F., Liu Y.L., Liu C.M., Hung S.I., Hwu H.G., Chen W.J. Neuregulin 1 gene and variations in perceptual aberration of schizotypal personality in adolescents. Psychol. Med. 2005, 35:1589-1598.
122. Lovestone S., Killick R., Di Forti M., Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 2007, 30:142-149.
123. Luciano M., Miyajima F., Lind P.A., Bates T.C., Horan M., Harris S.E., Wright M.J., Ollier W.E., Hayward C., Pendleton N., Gow A.J., Visscher P.M., Starr J.M., Deary I.J., Martin N.G., Payton A. Variation in the dysbindin gene and normal cognitive function in three independent population samples. Genes Brain Behav. 2009, 8:218-227.
124. Maekawa M., Watanabe M., Yamaguchi S., Konno R., Hori Y. Spatial learning and long-term potentiation of mutant mice lacking d-amino-acid-oxidase. Neurosci. Res. 2005, 53:34-38.
125. Maier W., Zobel A., Wagner M. Schizophrenia and bipolar disorder: differences and overlaps. Curr. Opin. Psychiatry 2006, 19:165-170.
126. Mao Y., Ge X., Frank C.L., Madison J.M., Koehler A.N., Doud M.K., Tassa C., Berry E.M., Soda T., Singh K.K., Biechele T., Petryshen T.L., Moon R.T., Haggarty S.J., Tsai L.H. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signalling. Cell 2009, 136:1017-1031.
127. McIntosh A.M., Job D.E., Moorhead W.J., Harrison L.K., Whalley H.C., Johnstone E.C., Lawrie S.M. Genetic liability to schizophrenia or bipolar disorder and its relationship to brain structure. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2006, 141:76-83.
128. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9:437-452.
129. Miyakawa T., Leiter L.M., Gerber D.J., Gainetdinov R.R., Sotnikova T.D., Zeng H., Caron M.G., Tonegawa S. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8987-8992.
130. Miyamoto Y., Yamada K., Noda Y., Mishina M., Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J. Neurosci. 2001, 21:750-757.
131. Miyoshi K., Honda A., Baba K., Taniguchi M., Oono K., Fujita T., Kuroda S., Katayama T., Tohyama M. Disrupted-in-schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol. Psychiatry 2003, 8:658-694.
132. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
133. Morris D.W., Murphy K., Kenny N., Purcell S.M., McGhee K.A., Schwaiger S., Nangle J.M., Donohoe G., Clarke S., Scully P., Quinn J., Meagher D., Baldwin P., Crumlish N., O'Callaghan E., Waddington J.L., Gill M., Corvin A.P. Dysbindin (DTNBP1) and the biogenesis of lyosome-related organelles complex 1 (BLOC-1): main and epistatic gene effects are potential contributors to schizophrenia susceptibility. Biol. Psychiatry 2008, 63:24-31.
134. Moser P.C., Hitchcock J.M., Lister S., Moran P.M. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res. Rev. 2000, 33:275-307.
135. Moskvina V., Craddock N., Holmans P., Nikolov I., Pahwa J.S., Green E., Owen M.J., O'Donovan M.C. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol. Psychiatry 2009, 14:252-260. Wellcome Trust Case Control Consortium.
136. Mouri A., Noda Y., Enomoto T., Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem. Int. 2007, 51:173-184.
137. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., Piven J., Crawley J.N. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav. 2004, 3:287-302.
138. Moy S.S., Perez A., Koller B.H., Duncan G.E. Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function. Brain Res. 2006, 1089:186-194.
139. Muir W.J., Pickard B.S., Blackwood D.H. Disrupted-in-schizophrenia-1. Curr. Psychiatry Rep. 2008, 10:140-147.
140. Murotani T., Ishizuka T., Hattori S., Hashimoto R., Matsuzaki S., Yamatodani A. High dopamine turnover in the brains of sandy mice. Neurosci. Lett. 2007, 421:47-51.
141. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72:29-39.
142. Numakawa T., Yagasaki Y., Ishimoto T., Okada T., Suzuki T., Iwata N., Taguchi T., Tatsumi M., Kamijima K., Straub R.E., Weinberger D.R., Kunugi H., Hashimoto R. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet. 2004, 13:2699-2708.
143. 2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 2004, 279:17980-17988.
144. Otte D.M., Bilkei-Gorzo A., Filiou M.D., Turck C.W., Yilmaz O., Holst M.I., Schilling K., Abou-Jamra R., Schumacher J., Benzel I., Kunz W.S., Beck H., Zimmer A. Behavioral changes in G72/G30 transgenic mice. Eur. Neuropsychopharmacol. 2009, 19:339-348.
145. O'Tuathaigh C.M.P., Babovic D., O'Meara G., Clifford J.J., Croke D.T., Waddington J.L. Susceptibility genes for schizophrenia: phenotypic characterisation of mutant models. Neurosci. Biobehav. Rev. 2007, 31:60-78.
146. O'Tuathaigh C.M., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., Harvey R., Waddington J.L. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 2007, 147:18-27.
147. O'Tuathaigh C.M.P., Desbonnet L., Waddington J.L. Neuregulin-1 signalling in schizophrenia: 'Jack of all trades' or master of some?. Exp. Rev. Neurother. 2009, 9:1-3.
148. O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Lai D., Harvey R., Croke D.T., Waddington J.L. Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:462-466.
149. O'Tuathaigh C.M., O'Sullivan G.J., Kinsella A., Harvey R.P., Tighe O., Croke D.T., Waddington J.L. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. Neuroreport 2006, 17:79-83.
150. Owen M.J., Craddock N., Jablensky A. The genetic deconstruction of psychosis. Schizophr. Bull. 2007, 33:905-911.
151. Pae C.U., Drago A., Kim J.J., Patkar A.A., Jun T.Y., Lee C., Mandelli L., De Ronchi D., Paik I.H., Serretti A. DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. Neurosci. Lett. 2008, 440:150-154.
152. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., Chen J. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J. Neurosci. 2008, 28:8709-8723.
153. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
154. Pelletier M., Achim A.M., Montoya A., Lal S., Lepage M. Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis. Schizophr. Res. 2005, 74:233-252.
155. Perkins D.O., Jeffries C., Sullivan P. Expanding the 'central dogma': the regulatory role of nonprotein coding genes and implications for the genetic liability to schizophrenia. Mol. Psychiatry 2005, 10:69-78.
156. Perkins D.O., Jeffries C.D., Jarskog L.F., Thomson J.M., Woods K., Newman M.A., Parker J.S., Jin J., Hammond S.M. MicroRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol. 2007, 8:R27.
157. Peters K., Wiltshire S., Henders A.K., Dragović M., Badcock J.C., Chandler D., Howell S., Ellis C., Bouwer S., Montgomery G.W., Palmer L.J., Kalaydjieva L., Jablensky A. Comprehensive analysis of tagging sequence variants in DTNBP1 shows no association with schizophrenia or with its composite neurocognitive endophenotypes. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2008, 147:1159-1166.
158. Pietersen C.Y., Bosker F.J., Doorduin J., Jongsma M.E., Postema F., Haas J.V., Johnson M.P., Koch T., Vladusich T., den Boer J.A. An animal model of emotional blunting in schizophrenia. PLoS ONE 2007, 2:e1360.
159. Pilowsky L.S., Bressan R.A., Stone J.M., Erlandsson K., Mulligan R.S., Krystal J.H., Ell P.J. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol. Psychiatry 2006, 11:118-119.
160. Piskulic D., Olver J.S., Norman T.R., Maruff P. Behavioural studies of spatial working memory dysfunction in schizophrenia: a quantitative literature review. Psychiatry Res. 2007, 150:111-121.
161. Pletnikov M.V., Ayhan Y., Nikolskaia O., Xu Y., Ovanesov M.V., Huang H., Mori S., Moran T.H., Ross C.A. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioural abnormalities reminiscent of schizophrenia. Mol. Psychiatry 2008, 13:173-186.
162. Powell C.M., Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol. Psychiatry 2006, 59:1198-1207.
163. Reichenberg A., Harvey P.D. Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. Psychol. Bull. 2007, 133:833-858.
164. Rietkerk T., Boks M.P., Sommer I.E., Liddle P.F., Ophoff R.A., Kahn R.S. The genetics of symptom dimensions of schizophrenia: review and meta-analysis. Schizophr. Res. 2008, 102:197-205.
165. Rimer M., Barrett D.W., Maldonado M.A., Vock V.M., Gonzalez-Lima F. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. Neuroreport 2005, 16:271-275.
166. Roy K., Murtie J.C., El-Khodor B.F., Edgar N., Sardi S.P., Hooks B.M., Benoit-Marand M., Chen C., Moore H., O'Donnell P., Brunner D., Corfas G. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:8131-8136.
167. Sachs G.S. A review of agitation in mental illness: burden of illness and underlying pathology. J. Clin. Psychiatry 2006, 67:5-12.
168. Sakae N., Yamasaki N., Kitaichi K., Fukuda T., Yamada M., Yoshikawa H., Hiranita T., Tatsumi Y., Kira J., Yamamoto T., Miyakawa T., Nakayama K.L. Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants. Hum. Mol. Genet. 2008, 17:3191-3203.
169. Sankoorikal G.M., Kaercher K.A., Boon C.J., Lee J.K., Brodkin E.S. A mouse model system for genetic analysis of sociability: C57BL/6J vs. BALB/cJ inbred mouse strains. Biol. Psychiatry 2006, 59:415-423.
170. Savonenko A.V., Melnikova T., Laird F.M., Stewart K.A., Price D.L., Wong P.C. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5585-5590.
171. Schneider C.W., Chenoweth M.B. Effects of hallucinogenic and other drugs on the nest-building behaviour of mice. Nature 1970, 225:1262-1263.
172. Seamans J.K., Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 2004, 74:1-58.
173. Selten J.P., Cantor-Graae E. Social defeat: risk factor for schizophrenia?. Br. J. Psychiatry 2005, 187:101-102.
174. Selten J.P., Cantor-Graae E. Hypothesis: social defeat is a risk factor for schizophrenia?. Br. J. Psychiatry Suppl. 2007, 51:s9-s12.
175. Shen S., Lang B., Nakamoto C., Zhang F., Pu J., Kuan S.L., Chatzi C., He S., Mackie I., Brandon N.J., Marquis K.L., Day M., Hurko O., McCaig C.D., Riedel G., St.Clair D. Schizophrenia-related neural and behavioural phenotypes in transgenic mice expressing truncated DISC1. J. Neurosci. 2008, 28:10893-11104.
176. Shi J., Gershon E.S., Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr. Res. 2008, 104:96-107.
177. Singer P., Feldon J., Yee B.K. Interactions between the glycine transporter 1 (GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour. Eur. Neuropsychopharmacol. 2009, 19:571-580.
178. St.Clair D. Copy number variation and schizophrenia. Schizophr. Bull. 2009, 35:9-12.
179. Stark K.L., Xu B., Bagchi A., Lai W.S., Liu H., Hsu R., Wan X., Pavlidis P., Mills A.A., Karayiorgou M., Gogos J.A. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat. Genet. 2008, 40:751-760.
180. Stefanis N.C., Trikalinos T.A., Avramopoulos D., Smyrnis N., Evdokimidis I., Ntzani E.E., Ioannidis J.P., Stefanis C.N. Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level. Biol. Psychiatry 2007, 62:784-792.
181. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T.T., Hjaltason O., Birgisdottir B., Jonsson H., Gudnadottir V.G., Gudmundsdottir E., Bjornsson A., Ingvarsson B., Ingason A., Sigfusson S., Hardardottir H., Harvey R.P., Lai D., Zhou M., Brunner D., Mutel V., Gonzalo A., Lemke G., Sainz J., Johannesson G., Andresson T., Gudbjartsson D., Manolescu A., Frigge M.L., Gurney M.E., Kong A., Gulcher J.R., Petursson H., Stefansson K. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 2002, 71:877-892.
182. Steuber-Buchberger P., Wurst W., Kühn R. Simultaneous Cre-mediated conditional knockdown of two genes in mice. Genesis 2008, 46:144-151.
183. Stone J.M., Morrison P.D., Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J. Psychopharmacol. 2007, 21:440-452.
184. Strekalova T., Spanagel R., Bartsch D., Henn F.A., Gass P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology 2004, 29:2000-2011.
185. Sweatt J.D. Experience-dependent epigenetic modifications in the central nervous system. Biol. Psychiatry 2009, 65:191-197.
186. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 2008, 199:331-388.
187. Szeszko P.R., Hodgkinson C.A., Robinson D.G., DeRosse P., Bilder R.M., Lencz T., Burdick K.E., Napolitano B., Betensky J.D., Kane J.M., Goldman D., Malhotra A.K. DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol. Psychol. 2008, 79:103-110.
188. Takao K., Toyama K., Nakanishi K., Hattori S., Takamura H., Takeda M., Miyakawa T., Hashimoto R. Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Mol. Brain 2009, 1:11.
189. Takao K., Yamasaki N., Miyakawa T. Impact of brain-behavior phenotyping of genetically-engineered mice on research of neuropsychiatric disorders. Neurosci. Res. 2007, 58:124-132.
190. Tan H.Y., Nicodemus K.K., Chen Q., Li Z., Brooke J.K., Honea R., Kolachana B.S., Straub R.E., Meyer-Lindenberg A., Sei Y., Mattay V.S., Callicott J.H., Weinberger D.R. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J. Clin. Invest. 2008, 118:2200-2208.
191. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia " just the facts" what we know in 2008 part 1: overview. Schizophr. Res. 2008, 100:4-19.
192. Tomppo L., Hennah W., Miettunen J., Jarvelin M.R., Veijola J., Ripatti S., Lahermo P., Lichtermann D., Partonen L., Ekelund J. Association of variants in DISC1 with psychosis-related traits in a large population cohort. Arch. Gen. Psychiatry 2009, 66:134-141.
193. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 2006, 60:141-151.
194. van OS J., Rutten B.P., Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and new directions. Schizophr. Bull. 2008, 34:1066-1082.
195. Verrall L., Walker M., Rawlings N., Benzel I., Kew J.N., Harrison P.J., Burnet P.W. d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur. J. Neurosci. 2007, 26:1657-1669.
196. Waddington J.L., Corvin A.P., Donohoe G., O'Tuathaigh C.M.P., Mitchell K.J., Gill M. Functional genomics and schizophrenia: endophenotypes and mutant models. Psychiat. Clin. N. Am. 2007, 30:365-399.
197. Walters J.T., Owen M.J. Endophenotypes in psychiatric genetics. Mol. Psychiatry 2007, 12:886-890.
198. Wang Q., Jaaro-Peled H., Sawa A., Brandon N.J. How has DISC enabled drug discovery?. Mol. Cell. Neurosci. 2008, 37:187-195.
199. Weickert C.S., Rothmond D.A., Hyde T.M., Kleinman J.E., Straub R.E. Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients. Schizophr. Res. 2008, 98:105-110.
200. Weickert C.S., Straub R.E., McClintock B.W., Matsumoto M., Hashimoto R., Hyde T.M., Herman M.M., Weinberger D.R., Kleinman J.E. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch. Gen. Psychiatry 2004, 61:544-555.
201. Weiner I. The " two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 2003, 169:257-297.
202. Wiedholz L.M., Owens W.A., Horton R.E., Feyder M., Karlsson R.M., Hefner K., Sprengel R., Celikel T., Daws L.C., Holmes A. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and " schizophrenia-related" behaviors. Mol. Psychiatry 2008, 13:631-640.
203. Williams H.J., Owen M.J., O'Donovan M.C. Is COMT a susceptibility gene for schizophrenia?. Schizophr. Bull. 2007, 33:635-641.
204. Willner P., Mitchell P.J. The validity of animal model of predisposition to depression. Behav. Pharmacol. 2002, 13:169-188.
205. Yamasaki N., Maekawa M., Kobayashi K., Kajii Y., Maeda J., Soma M., Takao K., Tanda K., Ohira K., Toyama K., Kanzaki K., Fukunaga K., Sudo Y., Ichinose H., Ikeda M., Iwata N., Ozaki N., Suzuki H., Higuchi M., Suhara T., Yuasa S., Miyakawa T. Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol. Brain 2009, 1:6.
206. Yee B.K., Balic E., Singer P., Schwerdel C., Grampp T., Gabernet L., Knuesel I., Benke D., Feldon J., Mohler H., Boison D. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J. Neurosci. 2006, 26:3169-3181.
207. Zammit S., Jones G., Jones S.J., Norton N., Sanders R.D., Milham C., McCarthy G.M., Jones L.A., Cardno A.G., Gray M., Murphy K.C., O'Donovan M.C., Owen M.J. Polymorphisms in the MAOA, MAOB, and COMT genes and aggressive behavior in schizophrenia. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2004, 128:19-20.
208. Zeng H., Chattarji S., Barbarosie M., Rondi-Reig L., Philpot B.D., Miyakawa T., Bear M.F., Tonegawa S. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 2001, 107:617-629.
209. Zhang R., Su B. MicroRNA regulation and the variability of human cortical gene expression. Nucleic Acids Res. 2008, 36:4621-4628.